testosterone decanoate: ester of testosterone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 155143 |
| CHEMBL ID | 1473654 |
| CHEBI ID | 35000 |
| SCHEMBL ID | 219795 |
| MeSH ID | M0123493 |
| Synonym |
|---|
| nsc26642 |
| 5721-91-5 |
| nsc-26642 |
| testosterone decanoate |
| 17beta-hydroxyandrost-4-en-3-one decanoate |
| NCGC00160513-01 |
| [(8r,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] decanoate |
| D08573 |
| testosterone 17beta-decanoate |
| testocaps (tn) |
| tox21_111863 |
| dtxsid5046198 , |
| dtxcid3026198 |
| cas-5721-91-5 |
| nsc 26642 |
| unii-ijw60lao6s |
| ijw60lao6s , |
| einecs 227-226-4 |
| AKOS015895429 |
| SCHEMBL219795 |
| CHEMBL1473654 |
| testosterone decanoate [who-dd] |
| testosterone caprinate |
| testosterone decanoate [mart.] |
| testosterone decanoate [ep monograph] |
| 17.beta.-hydroxyandrost-4-en-3-one decanoate |
| testosterone caprate |
| 3-oxoandrost-4-en-17.beta.-yl decanoate |
| gtpl7630 |
| CHEBI:35000 , |
| (17beta)-3-oxoandrost-4-en-17-yl decanoate |
| W-105480 |
| LBERVHLCXUMDOT-MPZZESAYSA-N |
| test decanoate |
| androst-4-en-3-one, 17-[(1-oxodecyl)oxy]-, (17.beta.)- |
| testosterone decanoate, european pharmacopoeia (ep) reference standard |
| testosterone decanoate for system suitability, european pharmacopoeia (ep) reference standard |
| testosterondecanoat |
| androst-4-en-3-one, 17-[(1-oxodecyl)oxy]-, (17b)- |
| DS-3319 |
| BCP17658 |
| Q27088963 |
| (1s,3as,3br,9ar,9bs,11as)-9a,11a-dimethyl-7-oxo-1h,2h,3h,3ah,3bh,4h,5h,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-1-yl decanoate |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Class | Description |
|---|---|
| steroid ester | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| USP1 protein, partial | Homo sapiens (human) | Potency | 35.4813 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
| AR protein | Homo sapiens (human) | Potency | 0.0228 | 0.0002 | 21.2231 | 8,912.5098 | AID743036; AID743040; AID743053 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 8.4852 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 5.8237 | 0.0002 | 29.3054 | 16,493.5996 | AID743075; AID743077; AID743079; AID743080 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 0.7498 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| geminin | Homo sapiens (human) | Potency | 13.3359 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 32.1968 | 0.0056 | 12.3677 | 36.1254 | AID624032 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 31.6228 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 33.4915 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (20.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (15.00%) | 5.53% |
| Reviews | 1 (5.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||